Founded in 1997, Braveheart Investment Group plc is a UK-based company that makes strategic investments in companies though it’s range of Special Purpose Vehicles, that it believes has potential and will outperform. It provides debt/equity and advisory services to the companies it back and helps them in decision making around operations, risk and strategy and it also services the investment requirements of public sectors, family businesses, business angels and high net worth individuals. The company’s shares are traded on the Alternative Investment Market of the London Stock Exchange since 2007 as LON: BRH.
The company operates through two categorical divisions that include Strategic Investments and Portfolio investments. The company’s Strategic investments include Gyrometric Systems limited, phasefocus holdings limited, Sentinel Medical Limited, Paraytec limited and Kirkstall limited. These investments help company to generate high value for its shareholders in future. The company owns 19.5% of the issued share capital of Gyrometric Systems, which has developed MDS2, a patented protected system of hardware and software which monitors the vibrations in rotating shafts at low and high speed and can detect minute irregularities in their motion.
In Phasefocus, the company holds 42.6% of the issued share capital; it has developed a series of patented computational imaging techniques such as Phasefocus Virtual lens and has a wide range of applications in Electron microscopy, cell imaging and engineering metrology. The company holds 38.40 % of the issued share capital in Sentinel Medical, which was formed as a spin-out from Paraytec to exploiting ways to detect and monitor bladder cancer. Paraytec limited is the wholly owned subsidiary of the company, which is engaged in developing high-performance detectors for the analytical and life sciences instrumentation sectors. The company holds 80% of stakes in Kirkstall Ltd and also provides significant management resource to Kirkstall, it has developed Quasi Vivo, which is an advance interconnected cell culture flow system that was engineered to provide in vivo-like conditions for cell growth.
The company also invests directly into the third party businesses that were made between 2002 and 2015, currently its portfolio investment include; Binx Health Ltd, Cizzle Biotechnology Ltd, Conjunct Ltd, Design led products ltd, Dimensional imaging ltd, Ectopharma ltd, Nitech solutions ltd, Pyreos ltd, Ryboquin company ltd, Traak systems ltd, Vascular floe technologies ltd and Zilico limited.
Capitol Business Park, 1 Capitol Court S75 3TZ United Kingdom